<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024371</url>
  </required_header>
  <id_info>
    <org_study_id>RTOC1</org_study_id>
    <nct_id>NCT04024371</nct_id>
  </id_info>
  <brief_title>Validating Reward-related Biomarkers (RTOC)</brief_title>
  <acronym>RTOC</acronym>
  <official_title>Validating Reward-related Biomarkers to Facilitate Development of New Treatments for Anhedonia and Reward Processing Deficits in Schizophrenia and Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>P1vital Products LTD.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BIOTRIAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University, School for Mental Health and Neuroscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deficits or abnormalities in reward processing are present in a number of psychiatric
      disorders. The overarching objective of the study is to conduct initial validation work
      towards optimising three experimental tasks - which have previously been shown to be
      sensitive to reward processing deficits - for future use in clinical trials.

      This initial validation work has the primary objective to uncover group differences in task
      outcome measures between healthy control participants, participants with Major Depressive
      Disorder (MDD) and participants with schizophrenia (SZ) using statistical analyses. This may
      provide some indications for the use of these tasks as clinically-relevant biomarkers.

      Primary aims include:

      (i) comparing the investigator's endpoint means and distributions to those in previously
      published data; (ii) replication of previously-reported differences between MDD/SZ vs.
      healthy control participants, and, (iii) exploring the relationship between task endpoints
      and subjective participant- and clinician-rated report of reward-related constructs (e.g.
      anhedonia, negative symptoms).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Grip effort outcome</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of hard task choices at different reward levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doors task outcome</measure>
    <time_frame>Day 1</time_frame>
    <description>&quot;Feedback negativity&quot;, an event-related potential (ERP) at approximately 300ms after feedback presentation indicating a favourable versus unfavourable outcome in paradigms in which the participant loses or wins money.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RL/WM task outcome</measure>
    <time_frame>Day 1</time_frame>
    <description>Accuracy as function of set size (difficulty)</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Depression</condition>
  <condition>Motivation</condition>
  <condition>Anhedonia, Physical</condition>
  <condition>Anhedonia, Social</condition>
  <condition>Negative Symptoms With Primary Psychotic Disorder</condition>
  <arm_group>
    <arm_group_label>HV</arm_group_label>
    <description>Humans aged 20-55 without a diagnosis of a psychiatric and neurological disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SZ</arm_group_label>
    <description>Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Schizophrenia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD</arm_group_label>
    <description>Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Self-rating Questionnaires</intervention_name>
    <description>Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)
Quick Inventory of Depressive Symptomatology (QIDS; 16 items)
Behavioral avoidance/inhibition Scales (BIS/BAS)</description>
    <arm_group_label>HV</arm_group_label>
    <arm_group_label>MDD</arm_group_label>
    <arm_group_label>SZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Measures of Reward processing/reinforcement learning</intervention_name>
    <description>Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)
Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)
Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)</description>
    <arm_group_label>HV</arm_group_label>
    <arm_group_label>MDD</arm_group_label>
    <arm_group_label>SZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Additional Schizophrenia-specific Questionnaires and Interviews</intervention_name>
    <description>Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)
Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)</description>
    <arm_group_label>SZ</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A sample of 37 completed individuals with MDD, 37 completed individuals with SZ, and a
        maximum of 80 healthy volunteers (without a neurological or psychiatric disorder) who will
        not differ on age or gender.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        General:

          1. Be able to provide signed and dated informed consent for study participation.

          2. Be male or female, aged between 20 and 55 years, inclusive.

          3. Be able to read, write, and speak the language in which psychometric tests are
             provided, with acceptable visual and auditory acuity (corrected if necessary).

          4. Unless otherwise stated, CNS medications to treat symptoms of MDD or SZ and other
             stable CNS conditions requiring medication is permitted in the MDD and SZ groups,
             provided the daily dose of medication has not been changed by more than +/- 30% in the
             last 4 weeks before the start of the study, and is not expected to change by a larger
             fraction while participating in the study.

        MDD

        Participants must:

          1. Have a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition
             (DSM-5) diagnosis of MDD, confirmed by the result of the MINI interview conducted by
             the site at screening. Subjects with a diagnosis of comorbid Generalized Anxiety
             Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder or specific phobia may
             be included.

          2. Meet the DSM-5 criteria for a current Major Depressive Episode, with the current
             depressive episode not having lasted longer than 6 months.

          3. If undergoing treatment, be currently treated with an antidepressant approved in this
             protocol for at least 4 continuous weeks. Psychological treatments (e.g., Cognitive
             Behaviour Therapy, Interpersonal Psychotherapy, Psychodynamic Psychotherapy etc.) are
             all permitted in this study regardless of frequency and duration.

        SZ

        Subjects must:

          1. Have a primary diagnosis of schizophrenia according to the Statistical Manual of
             Mental Disorders 5th edition (DSM-5), confirmed by the result of the MINI interview
             conducted by the site at screening. Subjects with a diagnosis of comorbid Generalized
             Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder or specific
             phobia may be included.

          2. Dose of antipsychotics not exceeding the equivalent of 6 mg risperidone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Hernaus, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis Hernaus, PhD</last_name>
    <phone>+31 43 388</phone>
    <phone_ext>3893</phone_ext>
    <email>dennis.hernaus@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherap</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Reif, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki, School of Medicine, Department of Clinical Pharmacology</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Papazisis, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese van Amelsvoort, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Pérez Sola, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Foti D, Hajcak G. Depression and reduced sensitivity to non-rewards versus rewards: Evidence from event-related potentials. Biol Psychol. 2009 Apr;81(1):1-8. doi: 10.1016/j.biopsycho.2008.12.004. Epub 2008 Dec 31.</citation>
    <PMID>19162124</PMID>
  </reference>
  <reference>
    <citation>Collins AGE, Albrecht MA, Waltz JA, Gold JM, Frank MJ. Interactions Among Working Memory, Reinforcement Learning, and Effort in Value-Based Choice: A New Paradigm and Selective Deficits in Schizophrenia. Biol Psychiatry. 2017 Sep 15;82(6):431-439. doi: 10.1016/j.biopsych.2017.05.017. Epub 2017 May 31.</citation>
    <PMID>28651789</PMID>
  </reference>
  <results_reference>
    <citation>Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. Schizophr Bull. 2015 Sep;41(5):1045-54. doi: 10.1093/schbul/sbv089. Epub 2015 Jul 3.</citation>
    <PMID>26142081</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anhedonia</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The RTOC clinical study has received funding from Boehringer Ingelheim International GmbH, H. Lundbeck, Janssen Pharmaceutica, Blackthorn Therapeutics, and F. Hoffmann-La Roche Ltd. All individual data will be made available to these parties.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

